

Pursuant to Rule 12b-23(a) of the Securities Exchange Act of 1934, as amended, the information for the 2020 Form 20-F of AstraZeneca PLC (the "Company") set out below is being incorporated by reference from AstraZeneca's "Annual Report and Form 20-F Information 2020" included as exhibit 15.1 to this Form 20-F dated and submitted on February 16, 2021.

References below to major headings include all information under such major headings, including subheadings, unless such reference is a reference to a subheading, in which case such reference includes only the information contained under such subheading. Unless the context otherwise requires, "AstraZeneca" or "Group" refers to the Company and its consolidated entities. Other information contained within AstraZeneca's "Annual Report and Form 20-F Information 2020" included as exhibit 15.1 to this Form 20-F, including graphs and tabular data, is not included in this Form 20-F unless specifically identified below. Photographs are also not included.

In addition to the information set out below, the information (including tabular data) set forth under the headings "Use of terms" on the inside front cover, "Strategic Report—Financial Review—Measuring performance" on page 84, and the tables on page 85, "Additional Information—Trade Marks" on page 279, "—Glossary" on pages 280 to 283 and "—Important information for readers of this Annual Report—Cautionary statement regarding forward-looking statements", "—Inclusion of Reported performance, Core financial measures and constant exchange rate growth rates", "—Statements of competitive position, growth rates and sales", "— AstraZeneca websites", "—External/third-party websites" and "—Figures" on page 284, in each case of AstraZeneca's "Annual Report and Form 20-F Information 2020" included as exhibit 15.1 to this Form 20-F dated February 16, 2021 is incorporated by reference. References herein to AstraZeneca websites, including where a link is provided, are textual references only and information on or accessible through such websites does not form part of and is not incorporated into this Form 20-F dated February 16, 2021. Reference to "audited" information (including graphs and tabular data) set forth under the heading "Corporate Governance—Directors' Remuneration Report" refers to procedures performed by the Company's external auditor in accordance with International Standards on Auditing (UK) ('ISAs (UK)') and applicable law and does not form part of the "Report of Independent Registered Public Accounting Firm" in Item 18 herein.

PART 1

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not applicable.

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3. KEY INFORMATION

A. *Selected Financial Data*

The information (including graphs and tabular data) set forth under the headings "Financial Statements—Group Financial Record" on page 243, "Additional Information—Shareholder Information—Issued share capital, shareholdings and share prices" and the first table that appears under "—Ordinary Shares in issue" on page 269, in each case of AstraZeneca's "Annual Report and Form 20-F Information 2020" included as exhibit 15.1 to this Form 20-F dated February 16, 2021 is incorporated by reference. The selected financial data incorporated by reference herein is derived from audited financial statements of the Company and its consolidated entities included in AstraZeneca's "Annual Report and Form 20-F Information 2020" included as exhibit 15.1 to this Form 20-F dated February 16, 2021. The audited financial statements of the Company and its consolidated entities have been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and International Financial Reporting Standards ("IFRSs") adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the European Union. The audited financial statements of the Company and its consolidated entities also comply fully with IFRSs as issued by the International Accounting Standards Board ("IASB").

B. *Capitalization and Indebtedness*

Not applicable.

C. *Reason for the Offer and Use of Proceeds*

Not applicable.

D. *Risk Factors*

The information (including tabular data) set forth or referenced under the heading "Additional Information—Risk" on pages 254 to 266 of AstraZeneca's "Annual Report and Form 20-F Information 2020" included as exhibit 15.1 to this Form 20-F dated February 16, 2021 is incorporated by reference.

ITEM 4. INFORMATION ON THE COMPANY

A. History and Development of the Company

The information (including tabular data) set forth under the headings “Additional Information–Shareholder Information–History and development of the Company” on page 268, “Strategic Report–Financial Review– Collaboration Revenue” on page 88, “Strategic Report–Financial Review–Financial position - 31 December 2020–Business combinations” on page 92, “Strategic Report–Financial Review–Financial Position - 31 December 2020–Investments, divestments and capital expenditure” on page 94, “Corporate Governance–Corporate Governance Report–Compliance with the UK Corporate Governance Code–Board Leadership and Company Purpose” on page 114 and “Additional Information–Important information for readers of this Annual Report– AstraZeneca websites” on page 284, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as exhibit 15.1 to this Form 20-F dated February 16, 2021 is incorporated by reference.

The United States Securities and Exchange Commission (the “SEC”) maintains a website at www.sec.gov which contains in electronic form each of the reports and other information that we have filed electronically with the SEC.

B. Business Overview

The information (including graphs and tabular data) set forth under the headings “Strategic Report–AstraZeneca at a glance” on pages 2 to 3, “Strategic Report–Chairman’s Statement” on page 4, “Strategic Report–Chief Executive Officer’s Review” on pages 5 to 6, “Strategic Report–Our Strategy and Key Performance Indicators” on pages 18 to 22, “Strategic Report–Performance in 2020” on pages 24 to 29; “Strategic Report–Performance in 2020–COVID-19 pandemic” on pages 28 and 29; “Strategic Report–Therapy Area Review” on pages 30 to 51, “Strategic Report–Business Review” on page 52 to 77, “Strategic Report– Risk Overview–Managing risk”, “–Risk Overview– Emerging risks”, “–Risk Overview–Climate risk”, “–Risk Overview–Risk management embedded in business processes” on page 78, “Strategic Report–Risk Overview–Brexit”, “–Risk Overview–COVID-19 pandemic” on page 79, “Corporate Governance–Corporate Governance Report–Other Governance information–Risk management and controls–Global Compliance and Internal Audit Services (IA)” on page 118, “Additional Information– Development Pipeline as at 11 February 2021” on pages 245 to 250, “Additional Information–Patent Expiries of Key Marketed Products” on pages 251 to 253, “Additional Information–Sustainability: supplementary information” on page 275, “Financial Statements–Notes to the Group Financial Statements–Note 1–Revenue” on pages 187 to 188, “Financial Statements–Notes to the Group Financial Statements–Note 6–Segment information” on pages 193 to 194, and “Additional Information–Important information for readers of this Annual Report–Statements of competitive position, growth rates and sales” on page 284, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2020” included as exhibit 15.1 to this Form 20-F dated February 16, 2021 is incorporated by reference.

Geographical Review

This section Item 4–“Information on the Company– Business Overview–Geographical Review” should be read in conjunction with Item 5–“Operating and Financial Review and Prospects–Operating Results” below.

	World			Emerging Markets			U.S.		Europe			Established ROW		
	Sales \$m	Actual %	CER %	Sales \$m	Actual %	CER %	Sales \$m	Actual %	Sales \$m	Actual %	CER %	Sales \$m	Actual %	CER %
2020														
Oncology:														
Tagrisso	4,328	36	36	1,208	59	63	1,566	24	748	58	56	806	18	16
Imfinzi	2,042	39	39	158	n/m	n/m	1,185	14	370	n/m	n/m	329	51	49
Lynparza	1,776	48	49	264	98	n/m	876	40	435	52	51	201	32	32
Calquence	522	n/m	n/m	6	n/m	n/m	511	n/m	2	n/m	n/m	3	n/m	n/m
Koselugo	38	n/m	n/m	n/m	n/m	n/m	38	n/m	–	n/m	n/m	n/m	n/m	n/m
Zoladex	888	9	13	561	14	20	5	(22)	140	4	4	182	1	1
Faslodex	580	(35)	(34)	180	(9)	(4)	55	(83)	221	(3)	(3)	124	(10)	(11)
Iressa	268	(37)	(36)	221	(23)	(22)	14	(21)	12	(82)	(82)	21	(57)	(57)
Arimidex	185	(18)	(16)	147	(3)	1	n/m	n/m	3	(88)	(88)	35	(23)	(24)
Casodex	172	(14)	(14)	133	4	6	n/m	n/m	3	(83)	(83)	36	(37)	(38)
Others	51	(47)	(46)	28	(1)	1	n/m	n/m	4	(41)	(40)	19	(69)	(69)
Total Oncology	10,850	25	26	2,906	31	36	4,250	23	1,938	36	35	1,756	11	10
CVRM:														
Farxiga	1,959	27	30	686	46	55	569	6	507	36	35	197	21	21
Brilinta	1,593	1	2	461	–	4	732	3	342	(3)	(3)	58	n/m	2
Onglyza	470	(11)	(10)	201	14	18	166	(28)	58	(16)	(17)	45	(12)	(11)
Bydureon	448	(18)	(18)	4	(62)	(59)	382	(17)	53	(20)	(20)	9	(32)	(31)
Byetta	68	(37)	(36)	8	(35)	(23)	37	(45)	14	(24)	(24)	9	(18)	(17)
Other diabetes	47	(10)	(10)	7	n/m	n/m	25	(37)	13	38	38	2	26	28
LokeIma	76	n/m	n/m	5	n/m	n/m	57	n/m	4	n/m	n/m	10	n/m	n/m
Crestor	1,180	(8)	(7)	748	(7)	(5)	92	(11)	129	(13)	(15)	211	(4)	(5)
Seloken/Toprol-XL	821	8	12	782	14	18	13	(66)	16	(35)	(35)	10	(11)	(10)
Atacand	243	10	15	175	9	17	10	(12)	35	17	17	23	15	15
Others	191	(30)	(30)	126	(35)	(34)	n/m	n/m	57	(5)	(4)	8	(60)	(61)
Total CVRM	7,096	3	5	3,203	8	12	2,083	(6)	1,228	7	6	582	2	2
Respiratory & Immunology:														
Symbicort	2,721	9	10	567	4	9	1,022	23	694	2	2	438	(1)	–
Pulmicort	996	(32)	(32)	798	(33)	(33)	71	(35)	73	(10)	(10)	54	(37)	(37)
Fasenra	949	35	34	12	n/m	n/m	603	25	203	72	70	131	33	32
Daliresp/Daxas	217	1	1	4	(9)	(8)	190	3	22	(14)	(13)	1	(10)	(8)
Bevespi	48	16	15	1	n/m	n/m	44	7	3	n/m	n/m	–	n/m	n/m
Breztri	28	n/m	n/m	14	n/m	n/m	5	n/m	–	n/m	n/m	9	n/m	n/m
Others	398	(15)	(15)	203	(15)	(16)	6	(12)	176	(14)	(15)	13	(15)	(7)
Total Respiratory & Immunology	5,357	(1)	n/m	1,599	(20)	(18)	1,941	17	1,171	6	5	646	n/m	1
Other:														
Nexium	1,492	1	2	757	1	4	169	(22)	71	12	10	495	9	8
Synagis	372	4	4	n/m	n/m	n/m	47	2	325	4	4	n/m	n/m	n/m
Flumist	295	n/m	n/m	1	n/m	n/m	70	n/m	219	n/m	n/m	5	n/m	n/m
Losec/Prilosec	183	(30)	(30)	152	(15)	(14)	6	(44)	20	(59)	(59)	5	(78)	(79)
Seroquel XR/IR	117	(39)	(37)	55	11	14	17	(48)	29	(67)	(67)	16	(19)	(18)
Others	128	(33)	(34)	6	(51)	(44)	55	(50)	58	(7)	(8)	9	6	(5)
Total Other	2,587	(1)	n/m	971	(2)	1	364	(17)	722	8	7	530	5	3
Total Product Sales	25,890	10	11	8,679	6	10	8,638	12	5,059	16	15	3,514	6	6